Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Baxter
McKesson
Moodys
Dow

Last Updated: September 25, 2022

VESICARE LS Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which patents cover Vesicare Ls, and what generic alternatives are available?

Vesicare Ls is a drug marketed by Astellas and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has twenty-four patent family members in twenty-two countries.

The generic ingredient in VESICARE LS is solifenacin succinate. There are thirty drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the solifenacin succinate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Vesicare Ls

A generic version of VESICARE LS was approved as solifenacin succinate by TEVA PHARMS USA on April 2nd, 2014.

  Try it Free

Summary for VESICARE LS
Drug patent expirations by year for VESICARE LS
Drug Prices for VESICARE LS

See drug prices for VESICARE LS

Recent Clinical Trials for VESICARE LS

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Brigitte SchürchPhase 4
Centre Hospitalier Universitaire VaudoisPhase 4
The Methodist Hospital Research InstitutePhase 4

See all VESICARE LS clinical trials

Pharmacology for VESICARE LS
Paragraph IV (Patent) Challenges for VESICARE LS
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
VESICARE LS Oral Suspension solifenacin succinate 1 mg/mL 209529 1 2021-05-27

US Patents and Regulatory Information for VESICARE LS

VESICARE LS is protected by one US patents and two FDA Regulatory Exclusivities.

Patents protecting VESICARE LS

Pharmaceutical composition comprising solifenacin
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

FDA Regulatory Exclusivity protecting VESICARE LS

NEW PRODUCT
Exclusivity Expiration: See Plans and Pricing

PEDIATRIC EXCLUSIVITY
Exclusivity Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astellas VESICARE LS solifenacin succinate SUSPENSION;ORAL 209529-001 May 26, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Astellas VESICARE LS solifenacin succinate SUSPENSION;ORAL 209529-001 May 26, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Astellas VESICARE LS solifenacin succinate SUSPENSION;ORAL 209529-001 May 26, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for VESICARE LS

See the table below for patents covering VESICARE LS around the world.

Country Patent Number Title Estimated Expiration
Portugal 2572717 See Plans and Pricing
Serbia 55044 FARMACEUTSKA KOMPOZICIJA KOJA SADRŽI SOLIFENACIN (PHARMACEUTICAL COMPOSITION CONTAINING SOLIFENACIN) See Plans and Pricing
Eurasian Patent Organization 023294 ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ СОЛИФЕНАЦИН (PHARMACEUTICAL COMPOSITION COMPRISING SOLIFENACIN) See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for VESICARE LS

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0801067 SPC/GB04/029 United Kingdom See Plans and Pricing PRODUCT NAME: SOLIFENACIN AND/OR PHARMACEUTICALLY ACTIVE SALT THEREOF; REGISTERED: NL RVG 29151 20031216; NL RVG 29152 20031216; UK PL 00166/0197 20040816; UK PL 0016/0198 20040816
0801067 04C0032 France See Plans and Pricing PRODUCT NAME: SUCCINATE DE SOLIFENACINE; NAT. REGISTRATION NO/DATE: NL 30 109 20040816; FIRST REGISTRATION: NL - RVG 29 151 20031216
0801067 C00801067/01 Switzerland See Plans and Pricing PRODUCT NAME: SOLIFENACIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 57203 12.05.2006
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
McKesson
Dow
Harvard Business School
Colorcon
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.